Table 1.
Study characteristics.
| Study | Year | Sample size (n) | Age (years) | Duration of infertility (years) | BMI (Kg/m2) | Gn | Intervention | Outcomes | NOS | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T/C | T | C | T | C | T | C | T | C | |||||
| Tu (30) | 2022 | 600/139 | 39.45 ± 2.99 | 39.98 ± 3.34 | 3(6–2) | 3(5–1) | 22.03 ± 2.62 | 22.29 ± 3.00 | HMG | MPA | CC/LE | ①②⑥⑧⑫⑬⑮ | 8 |
| Fan (31) | 2021 | 486/486 | 40.14 ± 3.72 | 40.25 ± 3.43 | 4.31 ± 2.96 | 4.35 ± 2.79 | 21.53 ± 2.66 | 21.38 ± 2.71 | HMG | MPA/MPA+EE | CC | ①④⑤⑦⑪⑫⑬ | 8 |
| Zheng (32) | 2020 | 59/57 | 38.41 ± 3.51 | 38.67 ± 3.34 | 4.44 ± 3.02 | 5.62 ± 2.15 | 22.17 ± 3.99 | 21.78 ± 4.09 | FSH | PC | CC | ①④⑩⑪⑫⑭⑮ | 8 |
| Yu(A) (33) | 2017 | 209/222 | 39.87 ± 5.41 | 40.47 ± 5.71 | 5(2,8) | 4(2,8) | 23.57 ± 3.61 | 23.78 ± 3.42 | FSH/HMG | MPA | CC | ①②⑮ | 8 |
| Yang (34) | 2022 | 47/247 | 39.00 ± 7.00 | 40 ± 6.00 | 3.00 ± 4.00 | 3.00 ± 4.00 | 23.20 ± 3.80 | 22.90 ± 4.40 | HMG | MPA | CC | ②④⑨⑩ | 7 |
| Zeng (35) | 2020 | 103/123 | 38.19 ± 4.96 | 37.98 ± 4.85 | 5.56 ± 4.9 | 4.88 ± 4.12 | 22.85 ± 2.57 | 22.34 ± 2.76 | FSH/HMG | MPA | CC | ②④⑨⑩⑪⑫ | 7 |
| Zhao (A) (23) | 2023 | 61/65 | 35.00, 41.00 | 35.00,42.00 | 1.50,5.50 | 1.00, 8.50 | 23.57 ± 2.78 | 23.68 ± 2.20 | HMG | DYG | CC | ①③⑥⑭ | 7 |
| Zhao (B) (36) | 2023 | 41/45 | 41.0(38.0,43.0) | 41.0(38.0,42.0) | 2.0(1.0, 4.0) | 2.0(1.0,4.5) | 21.3(19.35,23.56) | 21.72(20.07,25.25) | Gn | PC | CC/LE | ①②③⑥⑦⑧⑬⑮ | 7 |
| Zhang (25) | 2016 | 94/70 | 37.5 ± 5.7 | 36.8 ± 5.3 | 5.7 ± 4.1 | 5.0 ± 3.8 | NA | NA | Gn | MPA | CC+LE | ①③④⑤⑦⑨⑩⑪⑫ | 7 |
| Wang (37) | 2020 | 28/37 | 38.8 ± 5.3 | 38.2 ± 6.1 | 6.9 ± 1.7 | 6.8 ± 1.6 | NA | NA | FSH | MPA | CC/CC+LE | ④⑨⑩⑭ | 7 |
| Xu (38) | 2021 | 310/155 | 41.56 ± 3.70 | 42.32 ± 3.78 | 5.53 ± 4.91 | 6.27 ± 5.61 | 23.28 ± 2.84 | 23.56 ± 2.87 | FSH | MPA | CC | ②③④⑤⑦⑧⑨⑩⑪⑫⑮ | 7 |
| Yu(B) (39) | 2019 | 105/102 | <38 | <38 | 4.42 ± 0.38 | 3.63 ± 0.25 | 22.4 ± 0.34 | 22.5 ± 0.31 | HMG | MPA | CC | ①④⑦⑨⑩⑪⑫⑭ | 7 |
| Fu (24) | 2017 | 87/96 | 40.10 ± 4.50 | 39.90 ± 4.80 | 6.80 ± 4.10 | 6.30 ± 3.90 | 22.54 ± 4.07 | 22.00 ± 2.84 | HMG | DYG+LE | CC+LE | ①③④⑤⑦⑨⑩⑪⑫ | 6 |
| Liu (22) | 2020 | 52/56 | 41.13 ± 3.01 | 41.16 ± 2.63 | 4.02 ± 2.43 | 4.52 ± 3.03 | 22.34 ± 2.03 | 22.77 ± 1.97 | Gn | MPA | CC | ①②③④⑧⑨⑩⑪⑫⑮ | 6 |
T, trial group; C, control group; BMI, body mass index; Gn, gonadotropin; NA, not available; HMG, human menopausal gonadotropin; MPA, medroxyprogesterone acetate; CC, clomiphene citrate; LE, letrozole; EE, ethinyl estradiol; DYG, dydrogesterone; PC, progesterone capsules; FSH, follicle stimulation hormone; ① Cycle cancellation rate; ② Clinical pregnancy rate; ③ Optimal embryos rate; ④ Number of oocytes retrieved; ⑤ Fertilization rate; ⑥ Live birth rate; ⑦ Cleavage rate; ⑧ Embryo implantation rate; ⑨ E2 on the day of hCG; ⑩ LH on the day of hCG; ⑪ Duration of gonadotropin used; ⑫ Total dose of gonadotropin; ⑬ Premature LH surge rate; ⑭ Cumulative pregnancy rate; ⑮ Early miscarriage rate.